Consensus Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Market Closed - Nasdaq 04:00:00 2024-05-23 pm EDT 5-day change 1st Jan Change
29.35 USD -2.78% Intraday chart for Harmony Biosciences Holdings, Inc. +0.14% -9.13%

Evolution of the average Target Price on Harmony Biosciences Holdings, Inc.

Price target over the last 5 years

History of analyst recommendation changes

163f5290dc12b0622cc7d267e8.uSkTl9ZdCVlKh5tzXH9UqlLAON9-KrQSAC2F1RQeXQc.7mtg25MEbhUp1utFbTQF3TO1Vo4oX8BZV0bhvUZ9FjPhS3XD5gJOKTv_rw~b36f18c72db4e66d5ef1b1f58a90cd31
Mizuho Securities Cuts Price Target on Harmony Biosciences to $40 From $42, Maintains Buy Rating MT
Needham Cuts Price Target on Harmony Biosciences to $50 From $53, Maintains Buy Rating MT
Mizuho Boosts PT on Harmony Biosciences to $42 From $33 Ahead of Q4 2023 Earnings Announcement, Maintains Buy Rating MT
Goldman Sachs Adjusts Price Target on Harmony Biosciences Holdings to $28 From $25, Maintains Sell Rating MT
BofA Securities Downgrades Harmony Biosciences Holdings to Underperform From Neutral MT
Mizuho Raises Price Target on Harmony Biosciences to $33 From $28 on 'Continued Commercial Execution', Reiterates Buy Rating MT
Raymond James Adjusts Price Target on Harmony Biosciences to $27 From $26, Maintains Outperform Rating MT
Mizuho Slashes Price Target on Harmony Biosciences to $28 From $54, Keeps Buy Rating MT
Needham Cuts Price Target on Harmony Biosciences to $53 From $66, Keeps Buy Rating MT
Raymond James Adjusts Price Target on Harmony Biosciences to $26 From $58, Keeps Outperform Rating MT
Goldman Sachs Downgrades Harmony Biosciences Holdings to Sell From Neutral, Cuts Price Target to $31 From $40 MT
Berenberg Initiates Coverage on Harmony Biosciences at Buy, $59 Price Target MT
Raymond James Adjusts Price Target on Harmony Biosciences to $58 From $62, Maintains Outperform Rating MT
Mizuho Securities Cuts Price Target on Harmony Biosciences to $54 From $60, Maintains Buy Rating MT
Cantor Fitzgerald Adjusts Price Target on Harmony Biosciences Holdings to $75 From $71, Maintains Overweight Rating MT
BofA Securities Initiates Coverage on Harmony Biosciences With Neutral Rating, $35 Price Target MT
Goldman Sachs Adjusts Price Target on Harmony Biosciences Holdings to $43 From $49, Maintains Neutral Rating MT
Needham Trims Price Target on Harmony Biosciences Holdings to $67 From $70, Keeps Buy Rating MT
Mizuho Adjusts Price Target on Harmony Biosciences to $60 From $70, Reiterates Buy Rating MT
Piper Sandler Adjusts Harmony Biosciences Holdings Price Target to $70 From $62, Maintains Overweight Rating MT
Mizuho Adjusts Price Target on Harmony Biosciences Holdings to $70 From $60, Maintains Buy Rating MT
Needham Adjusts Price Target on Harmony Biosciences Holdings to $65 From $60, Maintains Buy Rating MT
Goldman Sachs Lowers Harmony Biosciences Holdings Price Target to $51 From $58, Maintains Neutral Rating MT
Jefferies Upgrades Harmony Biosciences Holdings to Buy From Hold, Adjusts Price Target to $61 From $57 MT
Goldman Sachs Raises Price Target on Harmony Biosciences to $58 From $56, Maintains Neutral Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
29.35 USD
Average target price
42.25 USD
Spread / Average Target
+43.95%
High Price Target
56 USD
Spread / Highest target
+90.80%
Low Price Target
28 USD
Spread / Lowest Target
-4.60%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Harmony Biosciences Holdings, Inc.

Mizuho Securities
Needham & Co.
Goldman Sachs
BofA Securities
Raymond James
Berenberg Bank
Cantor Fitzgerald
Piper Sandler
Jefferies & Co.
Oppenheimer
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock Market
  2. Equities
  3. HRMY Stock
  4. Consensus Harmony Biosciences Holdings, Inc.